Literature DB >> 2284687

Expression of two antigens defined by monoclonal antibodies in normal, benign and malignant human mammary tissues.

F Perrone1, S Ménard, M G Da Dalt, F Leoni, S Di Palma, C Patriarca, F Rilke, M I Colnaghi.   

Abstract

We examined the reactivity of two monoclonal antibodies (MAbs), MBrI and MBr8, on sections from normal breast tissues, benign lesions, primary infiltrating carcinomas and distant breast cancer metastases and compared the expression of the recognized antigens (CaMBr1 and CaMBr8 respectively) in these different normal and pathologic conditions. The expression of both antigens was found to significantly decrease in the neoplastic tissues, in comparison to normal breast tissue (34% vs 61% for MBr1 and 52% vs 86% for MBr8; p less than 0.001 for both). Atypical epithelial hyperplasia was found to be reactive on the same level (31%) of the tumors when tested with MBr1, whereas its reactivity was similar to that of normal tissues (78%) when MBr8 was used. Nonatypical epithelial hyperplasia showed the same reactivity with both MAbs (positive staining on about 50% of the cells). 65% of the "in situ" ductal carcinoma cases was MBr1-positive, whereas 50% was MBr8-positive; these values, when compared with the reactivity on normal glands, were significantly lower for MBr8, but not for MBr1. When testing sections from premenopausal women who had biopsies performed on different days during their menstrual cycle a correlation was found between the expression of CaMBr1 in normal breast epithelial cells and the stimulatory phase of the cycle. These findings suggest that both antigens are typical of normal breast and their expression could possibly decrease in pathologic tissues.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2284687     DOI: 10.1177/030089169007600601

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  1 in total

1.  Study of the biological and prognostic significance of the antigen CaMBr8 on breast carcinoma.

Authors:  P Facheris; F Perrone; S Ménard; S Andreola; P Bazzini; R Bufalino; S Canevari; N Cascinelli; E Colzani; G Di Fronzo
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.